Core Viewpoint - A shareholder has filed a securities class action lawsuit against Merck & Co., Inc. for alleged misrepresentations regarding the demand for its vaccine drug Gardasil in China, impacting investor confidence and inventory levels [1][2]. Group 1: Lawsuit Details - The lawsuit represents investors who purchased Merck securities between February 3, 2022, and February 3, 2025 [1]. - Allegations include that Merck lacked visibility into the demand for Gardasil in China, leading to inflated inventory levels at its distributor, Zhifei [2]. Group 2: Legal Process - Interested parties wishing to serve as lead plaintiff must file by April 14, 2025, with the role involving directing the litigation on behalf of the class [3]. - Shareholders can remain absent class members without taking action, and all representation is on a contingency fee basis, meaning no fees or expenses are required from shareholders [3]. Group 3: Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has represented large public and private pension funds [4]. - The firm has been recognized multiple times for its success in litigating class actions, being named to The National Law Journal's "Plaintiffs' Hot List" and listed in The Legal 500 for sixteen consecutive years [4].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Merck To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in Merck between February 3, 2022 and February 3, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Feb. 19, 2025 (GLOBE N ...

Core Viewpoint - A class action lawsuit has been filed against Merck & Co., Inc. for alleged violations of securities laws, specifically related to misleading statements about the demand for its product Gardasil in China and inflated inventory issues [1][4]. Group 1: Lawsuit Details - The lawsuit is based on violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 [1]. - Investors who purchased Merck's securities between February 3, 2022, and February 3, 2025, are encouraged to participate in the lawsuit [2]. - The class has not yet been certified, meaning potential participants are not currently represented by an attorney [3]. Group 2: Allegations Against Merck - The complaint alleges that Merck made false and misleading statements regarding its consumer activation and education efforts for Gardasil, particularly in China [4]. - The company was overly optimistic about Gardasil's demand while concealing negative facts about actual demand and inflated inventory held by its distributor, Zhifei [4]. - As a result of these misleading statements, investors suffered damages when the truth about Merck's situation was revealed [4].

NEW YORK, Feb. 18, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Merck & Co., Inc. ("Merck" or the "Company") (NYSE: MRK) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Merck investors who were adversely affected by alleged securities fraud between February 3, 2022 and February 3, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/merck-co-inc-lawsuit-submission-form? ...

SAN DIEGO, Feb. 15, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Merck & Co., Inc. (NYSE: MRK) securities between February 3, 2022 and February 3, 2025, both dates inclusive (the "Class Period"), have until April 14, 2025 to seek appointment as lead plaintiff of the Merck class action lawsuit.  Captioned Cronin v. Merck & Co., Inc., No. 25-cv-01208 (D.N.J.), the Merck class action lawsuit charges Merck and certain of Merck's top executives with violations o ...

SAN DIEGO, Feb. 14, 2025 /PRNewswire/ -- Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Merck & Co., Inc. (NYSE: MRK) securities between February 3, 2022 and February 3, 2025. Merck is a global healthcare company.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.The Allegations: Robbins LLP is Investigating Allegations that Merck & Co., Inc. (MRK) Misled Investors Regarding ...

NEW YORK, Feb. 13, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Merck & Co., Inc. (NYSE: MRK) between February 3, 2022 and February 3, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 14, 2025.So what: If you purchased Merck securities during the Class Period you ma ...

Buying a dividend stock at a cheap valuation can be a great move for several reasons. If a stock has declined in price but management has maintained its payout, new buyers can get a higher-than-usual yield from the investment. And if the underlying business is still in good shape, the share price decline may not be a lasting one -- so investors could profit from buying the stock and holding on for the eventual rebound.Three stocks that may be underrated options for dividend investors to consider today are P ...

SAN DIEGO, Feb. 13, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Merck & Co., Inc. (NYSE: MRK) securities between February 3, 2022 and February 3, 2025, inclusive (the "Class Period"), have until April 14, 2025 to seek appointment as lead plaintiff of the Merck class action lawsuit.  Captioned Cronin v. Merck & Co., Inc., No. 25-cv-01208 (D.N.J.), the Merck class action lawsuit charges Merck and certain of Merck's top executives with violati ...

Big Tech and pharmaceutical companies are accelerating the implementation of artificial intelligence in the healthcare industry. Just last month, AWS and General Catalyst announced their partnership to speed up the development and deployment of healthcare AI tools. GE Healthcare teamed up with AWS to build generative AI for medical use in 2024.  Now, a Thailand-based healthcare startup, HD, has built a marketplace, HDmall, to digitize the fragmented medical industry in Southeast Asia. The startup helps user ...